News

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™ Deal Showcases the Potential of Peptelligence® as the “Gold […]

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis Oral KORSUVA is now the […]

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ Study evaluating Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus […]

Enteris BioPharma to Present at New Rhein Healthcare Inaugural Industry Day 2019 Presentation to highlight Enteris’ development pipeline, led by Ovarest®, the company’s oral leuprolide product […]

Enteris’ lead program, Ovarest®, is designed to address a key endometriosis patient need by enabling the oral delivery of leuprolide   Boonton, NJ – March 5, […]

Boonton, NJ – December 18, 2018 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced […]

Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis Optimized tablet formulation achieved estradiol suppression in line […]